Log in

VYCO VYCOR MEDICAL INC OTC · United States

VYCOR MEDICAL INC (VYCO) news

Company Updates ·

Vycor Medical reports second quarter 2026 results

Revenue for the three months ended June 30, 2026 was $418,264, a decrease of 16% from the 2025 period. The company said most of the decline came from international markets.

Latest VYCOR MEDICAL INC news

  1. Company Updates

    Vycor Medical reports first quarter 2026 results

    Revenue for the three months ended March 31, 2026 was $458,540, an increase of $22,162, or 5%, over the 2025 period. The company said most of the growth came from international markets.

VYCOR MEDICAL INC annual financials

LineFY2025FY2024
Research and development$9,963$15,325
Net income (loss)-$72,426-$107,200
Cash from operations-$13,471$60,110
Cash and equivalents$86,982$105,648

Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $158,907.

Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice.

Questions about VYCOR MEDICAL INC

What is the ticker symbol of VYCOR MEDICAL INC?

VYCOR MEDICAL INC trades under the ticker VYCO on OTC.

Where is VYCOR MEDICAL INC listed?

VYCOR MEDICAL INC is listed on OTC.

Which country or territory is VYCOR MEDICAL INC listed under?

Our directory records VYCOR MEDICAL INC under United States.

Does aibio.space cover VYCOR MEDICAL INC?

aibio.space lists VYCOR MEDICAL INC among 2,820 public biotech companies and publishes its news here as stories appear.

Is VYCOR MEDICAL INC profitable?

VYCOR MEDICAL INC reported a net loss of $72,426 for the fiscal year ended Dec 31, 2025, and used $13,471 of cash in operations, per its annual report to the SEC.

How much does VYCOR MEDICAL INC spend on research and development?

$9,963 in the fiscal year ended Dec 31, 2025, per its annual report.

How much cash does VYCOR MEDICAL INC have?

$158,907 in cash at Jun 30, 2026, per its 10-Q.

What is the latest VYCOR MEDICAL INC (VYCO) stock news?

Our latest story on VYCOR MEDICAL INC, dated Aug 14, 2026: "Vycor Medical reports second quarter 2026 results". Revenue for the three months ended June 30, 2026 was $418,264, a decrease of 16% from the 2025 period. The company said most of the decline came from international markets. Source.

How can I follow VYCOR MEDICAL INC (VYCO) news?

Press Follow on this page to add VYCOR MEDICAL INC to your Following list, or subscribe to the aibio.space newsletter. We have published 2 stories naming VYCOR MEDICAL INC so far, in Company Updates.

Investor discussion: VYCOR MEDICAL INC

Members talk about VYCOR MEDICAL INC (VYCO). Reader posts, not aibio.space reporting, and not investment advice.

Rules
  1. Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
  2. Say whether you hold the stock. Every post states long, short or no position.
  3. No paid or sponsored posts. Do not post for anyone who pays or rewards you.
  4. No buy or sell calls and no price targets.
  5. No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
  6. No personal details and no spam. No links at all for your first 7 days as a member.

Posts that break the rules may be deleted without notice, and the account restricted or closed. See the terms and the privacy policy.

Stock chart

Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. Open OTC:VYCO on TradingView.

Listing details

VYCOR MEDICAL INC is a public biotech or pharmaceutical company listed on OTC under the ticker VYCO, recorded under United States. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.

Company
VYCOR MEDICAL INC
Ticker
VYCO
Listing
OTC
Country or territory
United States

Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. Tell us about a change. Work at this company? Claim this page.

Published and maintained by aibio.space. Not investment advice. How we work.

Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction

aibio.space

Full desks

Every other company has a starter desk. Search above to open one.

Settings

Appearance
Text size
Motion

Stops the news strip and the share rollers.

Your choices are saved in this browser only.

Free membership

Read aibio.space in full, free

Subscribe with your email address to read every story, company desk and profile in full. It costs nothing. In return, you agree that we may email you, including offers. One click to unsubscribe.

No card, no password. With email, we send one message to confirm your address first. With Google or Facebook we receive only your email address. Not investment advice.